Regeneron, Sanofi cut Praluent list tag 60% to match Repatha by Angus Liu Monday, February 11, 2019 After launching at about the same price—$14,000-plus—Praluent and Repatha again stand on par. But this time, it’s less than half the original sticker.
On heels of new price cuts, Amgen's Repatha hits wall at SCOTUS by Arlene Weintraub Wednesday, January 9, 2019 Amgen failed to keep Repatha rival Praluent off the market with a patent challenge, but it's hoping more price cuts will help it grab market share.
Express Scripts ramps up list-price pressure with new formulary by Eric Sagonowsky Tuesday, November 13, 2018 Express Scripts is rolling out a new formulary to assist drugmakers with lowering list prices.
For sale: Amgen chops 60% off Repatha's list price by Eric Sagonowsky Wednesday, October 24, 2018 It's common for drugmakers to offer behind-the-scenes rebates to win coverage for their drugs. But Amgen's big retail price cut is a rare move.
Sanofi, Regeneron closes in on sales-boosting CV nod by Tracy Staton Wednesday, September 12, 2018 Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.
Amgen asks Supreme Court to take up PCSK9 patent spat by Eric Sagonowsky Thursday, August 9, 2018 Amgen's aggressive legal bid to push Sanofi and Regeneron's rival PCSK9 drug off the market didn't work, but the big biotech hasn't given up.
With FDA nod, Amgen migraine med is ready to tap pent-up demand by Eric Sagonowsky Thursday, May 17, 2018 Aimovig has several more hurdles to clear before it can reach its lofty blockbuster goals—including persuading payers it's worth the cost.
Regeneron's Eylea delivers—again—but competitive threats loom by Eric Sagonowsky Thursday, May 3, 2018 Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.
Can Praluent's new formulary exclusive jump-start sales? by Eric Sagonowsky Wednesday, May 2, 2018 Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.